Kalow W., Britt BA, Terseau ME, Haist C.: Metabolic error of muscle metabolism after recovery from malignant hyperthermia . Lancet1970;2:895-898.
2.
Ellis FR, Harriman Dgf, Keaney NP, et al: Halothane-induced muscle contracture as a cause of hyperpyrexia . Br J Anaesth1971;43:721-722.
3.
Nelson TE, Flewellen EH, Gloyna DF: Spectrum of susceptibility to malignant hyperthermia—diagnostic dilemma . Anesth Analg1983;62:545-552.
4.
Nelson TE: Malignant hyperthermia in dogs. J Am Vet Med Assoc1991;198:989-994.
5.
Fujii J., Otsu K., Zorzato F., et al: Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science1991;253:448-451.
6.
MacLennan DH , Duff C., Zorzato F., et al: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature1990;343:559-561.
7.
McCarthy TV, Healy Sjm, Heffron Jja, et al: Localization of the malignant hyperthermia susceptibility locus to human chromosome 19 of 12-13.2. Nature1990;343:562.
8.
Gillard EF, Otsu K., Fujii J., et al: A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics1991;11:543.
9.
Fill M., Stefani E., Nelson TE: Abnormal human sarcoplasmic reticulum Ca2+ release channels in malignant hyperthermia skeletal muscle. Biophys J1991 ;59:1085-1090.
10.
Fill M., Coronado R., Michelson JR, et al: Abnormal ryanodine receptor channels in malignant hyperthermia . Biophys J1990;50:471-476.
11.
Nelson TE: Halothane effects on human malignant hyperthermia skeletal muscle single calcium-release channels in planar lipid bilayers. Anesthesiology1992;76:588-595.
12.
Mickelson JR , Gallant EM, Litterer LA, et al: Enhanced Ca2+ induced release by isolated sarcoplasmic reticulum vesicles from malignant hyperthermia pig muscle. J Biol Chem1988 ;263:9310-9315.
13.
Hawkes MJ, Nelson TE, Hamilton SL: [3H]-Ryanodine as a probe of changes in the functional state of the Ca2+ release channel in malignant hyperthermia. J Biol Chem1992; 267:6702- 6709.
14.
Valdivia HH , Hogan K., Coronado R.: Altered binding site for Ca2+ in the ryanodine receptor of human malignant hyperthermia. Am J Physiol1991;261:C237-C245.
15.
Gallant EM: Porcine malignant hyperthermia: No role for plasmalemma depolarization . Muscle Nerve1988;11:785-786.
16.
Lopez JR, Gerardi A., Lopez MJ, Allen DD: Effects of dantrolene on myoplasmic free [Ca2+] measured in vivo in patients susceptible to malignant hyperthermia. Anesthesiology1992;76:711-719.
17.
Wieland SJ, Fletcher JE, Rosenberg H., Gong QH: Malignant hyperthermia: Slow sodium current in cultured human muscle cells . Am J Physiol1989;257:C759.
Mejia-Alvarez R., Fill M., Garcia J., et al: Reduced transverse tubule Ca2+ currents in human malignant hyperthermia skeletal muscle. Biophys J1991;59:271a.
20.
Adnet PJ, Krivosic-Harber RM, Adamantidis MM, et al: Effect of Bay K 8644 on the magnitude of isoflurane and halothane contractures of skeletal muscle from patients susceptible to malignant hyperthermia . Anesthesiology1992;76:544-549.
21.
Frank JP, Harati Y., Butler IJ, et al: Central core disease and malignant hyperthermia syndrome. Ann Neurol1980;7:11-17.
22.
Denborough MA, Dennet X., Anderson R.: Central core disease and malignant hyperpyrexia . Br Med J1973 ;1:272-273.
23.
Kausch K., Grimm T., Janka M., et al: Evidence for linkage of the central core disease locus to chromosome 19 g. J Neurol Sci1990;98:549.
24.
King JO, Denborough MA: Anesthetic induced malignant hyperpyrexia in children. J Pediatr1973:83:37-40.
25.
McPherson EW , Taylor CA Jr: The King syndrome: Malignant hyperthermia, myopathy, and multiple anomalies. Am J Med Genet1981;8:159-165.
26.
Lingaraju N. , Rosenberg H.: Unexplained increases in serum creatine kinase levels: Its relation to malignant hyperthermia susceptibility . Anesth Analg1991;72:702-705.
